Astrazeneca
Clinical trials sponsored by Astrazeneca, explained in plain language.
A global pharmaceutical company focused on oncology, cardiovascular, and respiratory diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Real-World study tracks Selumetinib's impact on NF1 tumors in children
Disease control TerminatedThis study observes children aged 3 to 18 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas and are starting treatment with selumetinib. Researchers will track how well the drug shrinks or stabilizes tumors, how long patients stay on tre…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New biologic drug brazikumab tested for Crohn's – trial cut short
Disease control TerminatedThis study tested brazikumab, an experimental biologic drug, in 89 adults with moderate-to-severe Crohn's disease. Participants received either brazikumab, a placebo, or an active comparator (Humira) to see if the drug could improve symptoms and heal the gut lining. The trial was…
Phase: PHASE2, PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug shows promise for Long-Term control of ulcerative colitis
Disease control TerminatedThis study looks at the long-term safety of brazikumab, a drug given as a shot every 4 weeks, for people with moderate to severe ulcerative colitis. Participants had already taken part in an earlier study of brazikumab. The goal is to see if the drug remains safe over a longer pe…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug brazikumab aims to tame ulcerative colitis Flare-Ups
Disease control TerminatedThis phase 2 trial tested brazikumab in 242 adults with moderate-to-severe ulcerative colitis. Participants received either brazikumab or a placebo intravenously and then as injections over 54 weeks. The goal was to see if the drug could improve symptoms and heal the colon lining…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to free severe asthma patients from daily steroids
Disease control TerminatedThis Phase 3 trial tests whether tezepelumab, an injectable biologic, can help adults with severe asthma reduce their daily dose of oral corticosteroids while still keeping their asthma under control. Participants receive either tezepelumab or a placebo for 28 weeks, and doctors …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Crohn's drug trial halted early: what happened?
Disease control TerminatedThis study was designed to see if brazikumab is safe and tolerable over the long term for people with moderate to severe Crohn's disease. It enrolled 18 participants who had previously been in a related study. The trial was terminated early, meaning it did not reach its planned e…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental KRAS blocker tested in advanced cancers – trial halted early
Disease control TerminatedThis early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cet…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Asthma drug tested for stubborn nasal polyps – trial cut short
Disease control TerminatedThis phase 3 study tested the drug benralizumab in 295 adults with severe nasal polyps and eosinophilic chronic sinusitis. Participants received injections of benralizumab or a placebo every 4 to 8 weeks for about a year. The goal was to see if the drug could shrink polyps and im…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New heart drug AZD0233 begins first safety tests in healthy volunteers
Disease control TerminatedThis early-stage trial tested the safety of a new drug called AZD0233 in 84 healthy adults aged 18 to 50. The drug is being developed for dilated cardiomyopathy, a condition where the heart becomes enlarged and weak. Participants received either the drug or a placebo, and researc…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Kidney drug trial halted: did it help or harm?
Disease control TerminatedThis study tested a drug called sodium zirconium cyclosilicate (SZC) to see if it could slow down chronic kidney disease (CKD) in people who also have high potassium levels. Over 1,100 adults with moderate-to-severe CKD took SZC or a placebo alongside their regular blood pressure…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Lung cancer combo trial halted after just 4 patients
Disease control TerminatedThis phase 2 study tested a combination of the targeted drug osimertinib (Tagrisso) plus standard chemotherapy as a first treatment for advanced non-small cell lung cancer with uncommon EGFR mutations. Only 4 participants were enrolled before the study was terminated, so no meani…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Heart-Kidney drug trial halted early – what happened?
Disease control TerminatedThis early-stage trial tested an experimental drug called AZD3427 in 10 people with heart failure and reduced kidney function. The goal was to see if the drug could improve blood flow to the kidneys, measured with a special PET scan. However, the study was terminated early, so we…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New Heart-Kidney combo drug tested in tiny study
Disease control TerminatedThis early study tested a new drug called AZD5462 added to the standard medicine dapagliflozin in people with heart failure and moderate kidney disease. Only 8 participants were enrolled before the study was stopped. The goal was to see if the combination is safe and affects how …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
NASH registry study aims to map disease in chinese patients
Knowledge-focused TerminatedThis study was designed to collect information about Chinese patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Researchers planned to track how the disease is diagnosed and treated in real-world clinics, and to understand patients' knowledge and beliefs about …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Cancer drug interaction study halted after just one patient
Knowledge-focused TerminatedThis early-stage study aimed to see how the experimental drug ceralasertib affects the way the body processes three other drugs (Drug X, Y, and Z) in people with advanced solid tumours. Only one person was enrolled before the study was terminated, so no useful information was gat…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Russian NMOSD patients under the microscope: no new drug, just Real-World data
Knowledge-focused TerminatedThis study is not testing a new treatment. Instead, it observes how 100 adults with a rare autoimmune disease called NMOSD are managed in everyday Russian clinics. Researchers will collect medical records and follow patients over time to understand their symptoms, treatments, and…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Russian study seeks hidden cases of rare liver disease in kids
Knowledge-focused TerminatedThis study looks at children and teens in Russia who may have a rare genetic condition called lysosomal acid lipase deficiency (LAL-D). Researchers will check for the disease in up to 1,200 participants using blood tests and genetic testing. The goal is to understand how often LA…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Lung cancer study aims to predict dangerous lung inflammation
Knowledge-focused TerminatedThis study followed 83 people with advanced non-small cell lung cancer who were starting standard treatments. The goal was to collect information to help develop a digital tool that can spot early signs of pneumonitis/ILD, a serious lung inflammation that can occur as a side effe…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Asthma study aims to better understand uncontrolled disease in daily life
Knowledge-focused TerminatedThis study looked at adults with severe uncontrolled asthma in Germany to see how well their asthma was controlled over 12 months. Researchers used a simple questionnaire called AIRQ® to track symptoms, medication use, and doctor visits. The goal was to gather real-world informat…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:03 UTC
-
Hidden heart condition: study seeks to uncover missed diagnosis in heart failure patients
Knowledge-focused TerminatedThis study aims to find out how common transthyretin amyloidosis cardiomyopathy (ATTR-CM) is in Russian patients with a certain type of heart failure. Researchers will review medical records and then invite some patients for extra heart tests to confirm or rule out ATTR-CM. The g…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:47 UTC